Results 11 to 20 of about 25,547 (271)

EUCAST Technical Note on Voriconazole and Aspergillus spp. [PDF]

Clinical Microbiology and Infection, 2013
The European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has determined breakpoints for voriconazole against Aspergillus spp. This Technical Note is based on the EUCAST rationale document for voriconazole (available on the EUCAST website: http://www.eucast.org).
Cornelia Lass-Florl, M C Arendrup, M Cuenca-Estrella   +2 more
exaly   +5 more sources

EUCAST v.12.0 Review Focused on Changes

Annals of Clinical Microbiology, 2022
Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoint tables are commonly used as guidelines for the interpretation of antimicrobial susceptibility testing results.
Sae Am Song
doaj   +2 more sources

New definitions of susceptibility categories EUCAST 2019: clinic application

Revista Española de Quimioterapia, 2022
In January 2019, the European Committee for the Study of Antimicrobial Susceptibility (EUCAST) introduced some changes in the definitions of clinical categories for antibiotic susceptibility.
S. Díaz, O. Robles, J. G. Moya
semanticscholar   +4 more sources

Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST)

Journal of Clinical Microbiology, 2021
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is an international susceptibility testing committee, organized by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) and functioning as the breakpoint ...
C. Giske, J. Turnidge, R. Cantón, G. Kahlmeter   +3 more
semanticscholar   +3 more sources

The Influence of Medium Composition on EUCAST and Etest Antifungal Susceptibility Testing

Journal of Fungi, 2023
There is an ongoing effort to optimize and revise antifungal susceptibility testing (AFST) methods due to the rising number of fungal infections and drug-resistant fungi.
Roya Vahedi-Shahandashti, Melanie Maria Stubenböck, C. Lass‐Flörl   +2 more
semanticscholar   +4 more sources

Antifungal susceptibility and molecular characterization of clinical and environmental isolates of Schizophyllum commune [PDF]

Journal of Clinical Microbiology
Schizophyllum commune is a cosmopolitan, saprophytic basidiomycete known to cause respiratory tract infections following spore inhalation. Management of such infections remained poorly defined, and antifungal susceptibility testing may provide valuable ...
Grégoire Pasquier, Pierre-Olivier Harmand, Laura Le Feur, Emilie Guemas, Anne Pauline Bellanger, Danièle Maubon, Anne Favel, Claire Cottrel, Lilia Hasseine, Marcela Sabou, Eric Dannaoui, Arnaud Fekkar, Anne-Cécile Normand, Jean-Pierre Gangneux, Laurence Delhaes, Milène Sasso, Laurence Lachaud   +16 more
doaj   +2 more sources

EUCAST Ibrexafungerp MICs and Wild-Type Upper Limits for Contemporary Danish Yeast Isolates

Journal of Fungi, 2022
Ibrexafungerp is a novel triterpenoid antifungal that inhibits glucan synthase and thus fungal cell wall synthesis. We examined the in vitro activity against contemporary clinical yeast, investigated inter-laboratory and intra-laboratory variability ...
Karin M. Jørgensen, Karen M. T. Astvad, Rasmus K. Hare, Maiken C. Arendrup   +3 more
doaj   +2 more sources

Emerging Terbinafine Resistance in Trichophyton : Clinical Characteristics, Squalene Epoxidase Gene Mutations, and a Reliable EUCAST Method for Detection [PDF]

Antimicrobial Agents and Chemotherapy, 2019
In recent years, cases involving terbinafine-resistant Trichophyton isolates have been reported increasingly, particularly in India. We present 14 cases of terbinafine treatment failure in Trichophyton-infected Danish patients due to acquired resistance.
Ditte Marie Lindhardt Saunte, Rasmus Krøger Hare, Karin Meinike Jørgensen, René Jørgensen, Mette Deleuran, Claus Zachariae, Simon Francis Thomsen, Lars Bjørnskov-Halkier, Kristian Kofoed, Maiken Cavling Arendrup   +9 more
openalex   +2 more sources

In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies

Journal of Fungi, 2021
Ibrexafungerp is a new orally-available 1,3-β-D-glucan synthesis inhibitor in clinical development. Its in vitro activity and that of amphotericin B, voriconazole, and micafungin were evaluated against a collection of 168 clinical isolates of Aspergillus
Olga Rivero-Menendez, Juan Carlos Soto-Debran, Manuel Cuenca-Estrella, Ana Alastruey-Izquierdo   +3 more
doaj   +2 more sources

Digital Infrastructure for Antimicrobial Susceptibility Testing and Surveillance: A CLSI and EUCAST-Based Model for Resource-Limited Settings. [PDF]

JMIR Form Res
Mbarushimana D, Adegboyega TT, Jean Damascene G, Bale MI, Damascene BJ, Marie Francoise K, Innocent I, Alexis R, Adeyemo RO, Issa B, Akinola SA, Adedeji AA, Evariste M, Albert B, Felicite M, Sylvain H, Habarugira F, Sinumvayo JP, Noel R, Theogene T, Jules NM, Christian N.   +21 more
europepmc   +2 more sources